Invivyd News and Activities

Invivyd is a company listed under the stock ticker IVVD (US).

View the org chart displaying its 21 main executives

Most searched biographies at Invivyd

• Tamsin Berry, Director
• Kevin Mclaughlin, Director
• Paul Bolno, Director

Popular executive movements at Invivyd

• Michael Mina has joined the company as Chief Medical Officer  (posted on March 6 2026).
• Paul Bolno has joined the company as Director  (posted on September 25 2025).
• Danielle Looney, who was Talent and Human Resources Business Partner, is promoted to Senior Director of Human Resources  (posted on September 17 2025).

Click here to view some more movements at Invivyd

Create your alert
to follow the executive moves at Invivyd.

Invivyd has 2,405 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).

Popular M&A news in Biotechnology

• IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).
• NewLimit has just announced a $435 Million fundraising (posted on June 3 2026).
• Rallybio and Avenzo Therapeutics have announced they will merge  (posted on June 1 2026)..

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Valerie Hanote - Non-Executive Director at Eurofins

Learn more about the Biotechnology industry

Press releases by Invivyd

• Invivyd to Participate in Upcoming Investor Events | Invivyd
• Invivyd Reports First Quarter 2026 Financial Results and Recent Business Highlights | Invivyd
• Invivyd and Collaborators Author New Manuscript Evaluating Early Tolerability of COVID Monoclonal Antibody and Comparing Results to COVID Vaccination | Invivyd
• Invivyd to Host First Quarter 2026 Financial Results and Corporate Update Call on May 14, 2026 | Invivyd
• Invivyd Announces Chairman Marc Elia to Speak at POLITICO Health Care Summit | Invivyd
• Invivyd Announces REVOLUTION Program Progress and Advancement of Novel, Potential First- and Best-in-Class Measles Monoclonal Antibody Candidate VMS063 for Treatment and Prevention of Measles | Invivyd
• Invivyd Launches “Antibodies for Any Body” in Partnership with World Champion Skier Lindsey Vonn to Inspire Actions that Help Support Immune Health | Invivyd
• Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Invivyd
• Invivyd Announces Presentation at the World Vaccine Congress Washington | Invivyd
• Invivyd Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Recent Business Highlights and DECLARATION Clinical Trial Updates | Invivyd
• View more press releases Close

Social media about Invivyd

• Invivyd on Wikipedia, Google News & Yahoo Finance
• Invivyd on LinkedIn, X (Twitter) & YouTube